Every material Form 8-K Envista filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Envista reported third-quarter 2024 sales of $601.0 million, down from $631.3 million a year earlier, with core sales down 5.3%. GAAP net income fell to $8.2 million, or $0.05 per diluted share, from $21.5 million, and adjusted diluted EPS fell to $0.12 from $0.43. The company kept its full-year 2024 outlook of core sales growth of -1% to -4% and adjusted EBITDA margins of 10% to 12%, but nine-month GAAP results include a $1.15 billion goodwill and intangible asset impairment.
Q3 2024 sales $601.0 million vs. $631.3 million in Q3 2023; core sales declined 5.3%.
Q3 GAAP net income $8.2 million ($0.05 per diluted share) vs. $21.5 million ($0.12) a year earlier.
Adjusted EBITDA $54.9 million vs. $123.5 million; adjusted diluted EPS $0.12 vs. $0.43.
2024 guidance unchanged: core sales growth of -1% to -4% and adjusted EBITDA margins of 10% to 12%; company expects a return to growth in Q4.
Envista reported second-quarter 2024 sales of $633.1 million, down from $662.4 million a year earlier, and a net loss of $1,151.6 million, or $6.69 per share, driven by a $1,153.8 million non-cash goodwill and intangible asset impairment. Adjusted EPS fell to $0.11 from $0.43, and the company guided to a 1% to 4% core sales decline for full-year 2024, with a further decline expected in the third quarter.
Q2 sales were $633.1 million, down from $662.4 million; core sales declined 3.2%.
Net loss was $1,151.6 million, or $6.69 per share, including a $1,153.8 million non-cash impairment charge.
Adjusted EPS was $0.11 versus $0.43; adjusted EBITDA was $63.0 million versus $126.2 million.
For 2024, the company expects core sales to decline 1% to 4% and adjusted EBITDA margins of 10% to 12%.
Envista Holdings appointed Eric Hammes, formerly Vice President of Corporate Financial Planning & Analysis at Rockwell Automation, as Senior Vice President and Chief Financial Officer, effective August 8, 2024. He succeeds Stephen Keller, who has served as Interim Principal Financial Officer since September 2023 and will return to leading investor relations. The filing also announces two other leadership appointments, a change in top finance leadership that shareholders may track.
Eric Hammes becomes CFO effective August 8, 2024; he is 49 and previously held senior finance roles at 3M
Hammes' pay includes a $575,000 base salary, a 75% target incentive, and a one-time lump sum bonus of $1,020,000 subject to a 12-month clawback
Stephen Keller, Interim Principal Financial Officer since September 2023, will return to his previous role leading investor relations
Stefan Nilsson joins as President, Nobel Biocare, effective July 15, 2024; Veronica Acurio joins as President, Orthodontics, effective August 2, 2024
Envista Holdings disclosed that Eric Conley, SVP and President of Orthodontics, will step down effective June 3, 2024 to pursue another opportunity. The company said the decision was not the result of any disagreement with the company.
Eric Conley notified Envista on May 27, 2024 that he will step down as SVP and President, Orthodontics.
His departure takes effect June 3, 2024.
Conley is leaving to pursue another opportunity; the filing states no disagreement with the company.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Envista filing is on SEC EDGAR ↗. 8-K briefs of other companies →